Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias

NCT01396499 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: BKM120

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]